The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Exactly as I said in my 21:23 post last night, DTW. Whilst marvellous to see the potential grow as they’re going after numerous indications (with partners), it’s a jam tomorrow approach. I’d rather have seen AVA6k for STS get to market and then use those revenues to fund broadening later down the line. They’ve expedited Tx, but paid a price for it (well, I have).
Same as yesterday for me, I’m not interested in reading their moronic spam. The trial continues, they’ll access funds one way or another and ultimately value will out. Rabid scum, burn in hell. Have a good day LTHs.
Different ring to it today. Ah well, I was right, they certainly accessed funds. Time to go Alan. Could have easily raised many more millions at a higher price, his awful decisions and strategic fumbles have led us here.
The day presentation was an own goal. Promised much, but only a summary was given to make a big splash with full data at AACR. Well I hope they enjoy the trip and the poster is printed on the finest quality paper. If there's no commercial upside to it then it's Alan prioritising showing off academically over the shareholders he works for. They need to come back from their holibobs with some licence deals. Value curve my f**king *rse.
DTW, they need to get ava6k to market asap for STS imo. Expanding and broadening and increasing the trial seems like madness when you've just raised at a fraction of the price from a few months earlier. If they got a product to market they'd have all the time and cash they need to do all those things. It's a strategic mess. I'll try to be fair - perhaps the FDA are pulling the strings and their hands are tied. If not, then Alan is the inept decision maker I thought he was. These strategy decisions aren't difficult ones. If ava6k has the potential to become the SoC overnight, make it happen.
Which is mental. Imagine then compounding that by claiming it's a strategy and buying Coris and chucking more vital cash away. Wouldn't have been an issue if they were bringing in profit. Which idiot carried out that due diligence.
He smugly bragged of optionality, dangled the non dilutive funding carrot on more than one occasion then sold the company short due to his own utter stupidity in spunking vital cash up the Dx wall. The garbled RNS aligns with the aimless leadership.
Complete incompetence and a strategic shambles. Raising for a M&A strategy then turning around to offload it pretty much immediately - no doubt at a loss - to fund Tx where the value is. No sh.t Sherlock, focusing the cash on Tx was always the play. If that Dx cash hadn't been poured down the drain they'd have been sat with the cash they needed. Just go Alan. Before you do any more harm to a business with huge potential.
Same as yesterday for me, I’m not interested in reading their moronic spam. The trial continues, they’ll access funds one way or another and ultimately value will out. Rabid scum, burn in hell. Have a good day LTHs.
Just popping in, looks like the latest news is that Derek reckons it doesn’t work - despite the presentation of data that showed it’s working perfectly well as designed. A worthy bin resident. Meanwhile Charles Archer, the human equivalent of badly coded AI has spaffed out some more waffle to provide the goons some more ammo.
Here’s an idea. Why not take out another CLN to pay off heights? If you’re going for a death spiral, go all in. Or just crack on with the 20p placing.
Time to head off again….
All of the above. Same as yesterday for me, I’m not interested in reading their moronic spam. The trial continues, they’ll access funds one way or another and ultimately value will out. Rabid scum, burn in hell. Have a good day LTHs.